|
|
|
201-500 employees
View all
|
|
Research
|
|
Calle de Eduardo Primo Yúfera, 3 (junto Oceanográfico), Valencia, Valencia 46012, ES
|
|
For almost 50 years researchers of this Center have made great efforts to place our Center among those achieving excellence in research. Several breakthroughs have been made in key areas such as Regenerative medicine, cancer, new therapies, neuronal damage.
Our goal is to do biomedical research including basic genes, targets, molecular and cellular processes, nanomedicine and Computational Medicine and its translation into clinical practice We have special interest in personalized medicine, cancer, rare diseases, metabolic, and cognitive and functional impairment.
In addition to the objective of advancing into biomedical knowledge of impact, at the CIPF we want to promote the translation of the research conducted by our groups, who have extensive experience in the above mentioned subjects, either to the sanitary system for improving the health of citizens, with the potential to establish a more personalized medicine, either to the production system in terms of results which are Patentable or exploitable.
In the CIPF are five main research areas:
Neurological Impairment Program.
Rare & Genetic Diseases Program.
Computal Genomics Program.
Molecular Mechanisms Of Disease Program.
Advanced Therapies Program.
For more information on any of our programs please visit our website.
|
Centro De Investigación Príncipe Felipe (CIPF) Email Formats | Example Email Formats | Percentage |
---|---|---|
{f}{last} | [email protected] |
52.94%
|
The widely used Centro De Investigación Príncipe Felipe (CIPF) email format is {f}{last} (e.g. [email protected]) with 52.94% adoption across the company.
To contact Centro De Investigación Príncipe Felipe (CIPF) customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.